Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Jun 11, 2022 12:08pm
276 Views
Post# 34749301

RALI-Dx importance....(Andrew Morris shares)

RALI-Dx importance....(Andrew Morris shares)

Data can help the system focus its efforts on those who are truly going to become sick.

This was part of the drive to develop our RALI-Dx test for COVID, which is meant to triage patients in the emergency department who are positive for COVID-19. The test’s endpoint is the probability of intubation, and it uses IL-6 as a biomarker — rather than relying on blunter tools like known comorbidities or age and weight — to decide whether to send a patient home or focus aggressive treatment on them. As the shortage of hospital beds has become less of an acute crisis, the FDA has shifted its priorities on this particular test (though Health Canada is looking at the test under expedited review), but the response from the provider community shows that they value this kind of data being made available to them. After all, the RALI-Dx test is a derivative of our TORdx lung transplant product, with RALI-Dx’s broader application being to triage any patient in respiratory distress coming into the hospital, not just COVID positive patients.

<< Previous
Bullboard Posts
Next >>